New Drugs of 2012, Part 2

Pharmacy TimesMarch 2013 Central Nervous System
Volume 79
Issue 3

New Drugs of 2012, Part 2

Michael A. Mancano, PharmD

Clinical Professor of Pharmacy PracticeChair, Department of Pharmacy PracticeTemple University School of PharmacyPhiladelphia, Pennsylvania Clinical Consultant, Pennsylvania HospitalDepartment of PharmacyPhiladelphia, Pennsylvania


The following contributors have no relevant financial relationships with commercial interests to disclose.


Michael A. Mancano, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff

Judy V. Lum, MPA; and Elena Beyzarov, PharmD

Pharmacy Times Editorial Staff

Jennifer Whartenby and David Allikas

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss the clinical indications of the new drugs approved by the FDA in 2012.
  • Explain the various mechanisms of action of the drugs discussed within this activity.
  • Recognize the clinically relevant drug interactions and adverse reactions for the drugs reviewed in this activity.
  • Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: March 10, 2013

Expiration date: March 10, 2015

Estimated time to complete activity: 2 hours

Fee: This lesson is free online

Click here to view this activity.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.